Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...
Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a ...
Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the ...
SOXRC Regimen Improves Responses Versus Chemo Alone in Advanced Gastric Cancers ...
Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...
A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...
A study showed that patients with prostate cancer should consider the long-term side effects of treatments before deciding on ...
CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable. There have been a number ...
Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain ...
Embrace Gratitude: I must reflect on what I’m thankful for each year. This practice reshaped my perspective on life. Create a ...
In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback